רווח תפעולי לפני פחת: Qiagen NV (QGEN)

The absolute operating profit metric on GURU.Markets contains data on Qiagen N.V. (QGEN), a molecular diagnostics innovator creating the foundation for personalized medicine. The indispensable nature of their nucleic acid isolation kits ensures a stable monopoly position in forensics. Meanwhile, the 742.42 metric confirms the current level of profitability, which is based on high-margin sales of test systems and reagents for research laboratories.

Qiagen N.V. (QGEN) generates its primary revenue through the supply of reagents and equipment for nucleic acid analysis. This indicator captures daily operating profit, adjusted for depreciation and taxes. By analyzing the EBITDA timeline, an investor assesses the efficiency of the company's commercial asset utilization. Growth in this metric confirms the scaling of consumables sales within the clinical sector. Stable dynamics reinforce the asset's status as a fundamentally resilient business.